Phase 1/2 Study of Mobocertinib in mNSCLC With EGFR Exon 20 Insertions: EXCLAIM and Platinum-Pretreated Patients Cohorts

February 19, 2021 | Jyoti D. Patel, MD, FASCO

Jyoti D. Patel, MD, FASCO, presents slides from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) from the phase 1/2 study of mobocertinib in non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions.